In this issue of the journal, Bembea et al. 1 continue the ECMO community's collective search for the holy grail of anticoagulation monitoring for patients on extracorporeal membrane oxygenation (ECMO) in hopes of minimizing the arguably excessive complications of bleeding and thrombosis experienced internationally. 2 Despite many limitations of their prospective observational study, including small numbers and dramatic heterogeneity of their patient populations, one cannot argue with their demonstration of the lack of correlation between our bedside activated clotting time (ACT) testing and more specific measures of anticoagulation, such as anti-Factor Xa. However, what do we make of it all? Does the lack of correlation directly contribute to their relatively high rates of both thrombotic and hemorrhagic complications?
Extracorporeal membrane oxygenation clinicians have long recognized the limitations of the global test for anticoagulation upon which we have long relied: the activated clotting time. Quick, relatively cheap and readily available, and reasonably reliable in most patients, it has become our mainstay of management. But we also recognize that when it is off, it can be way off, effected by a variety of factors, including sepsis, D-dimers, hypothermia, and, perhaps most commonly on ECMO, thrombocytopenia. Thus, we seek more specific determinants of preventing circuit thrombosis and patient hemorrhage. Unfortunately, in our desire to find a better monitor, we may be creating a system of "overmeasure and overtreat," with increasing use Department of Pediatric Surgery, Division of Cardiovascular Surgery antithrombin III, and platelets in all patients, in our attempt to reduce the complications in the minority. For example, in this study, the use of AT was discretionary and the use of FFP common. However, in the absence of sepsis and true disseminated intravascular coagulopathy (DIC), I personally have found little use for routine FFP, and rarely give AT III, despite using Amicar fairly liberally, yet I have experienced less circuit clotting and complications than reported in this study or in the Extracorporeal Life Support Organization database. In fact, I usually allow the international normalized ratio (INR) to creep up into the 3 or 4 range, depending on the patient, not only because I think FFP transfusions increase the risk of circuit clots (particularly if you give it to the circuit, not the patient!) but also because monitoring the patient's ability to correct the INR on their own is a critical measure of recovering hepatic synthetic function. As a surgeon with many young patients running around (literally) with therapeutic INRs of 3-4 for their mechanical valve prostheses, I see little harm in allowing the INR to rise moderately in patients who are not actively bleeding and lying flat in bed.
As for the ACT specifically, while recognizing its many limitations, it continues to have many advantages. In most stable patients, it continues to reflect an appropriate trend of heparin effect, and when it changes, especially unexpectedly or dramatically in either direction, that is when we need to rely more on our additional tests to sort out the source of the problem and reassess our state of anticoagulation. Relying on the ACT alone without additional monitoring of anticoagulation in patients with obvious coagulopathy from sepsis, systemic inflammatory response syndrome (SIRS) and DIC, makes about as much sense as letting the patient's parents sit at bedside and run the ECMO circuit. Like most tools in medicine, understanding the limitations of the test is the key to using it appropriately so that a significant upward trend in ACT despite reduction in heparin dosing (or vice versa) cannot be ignored and must be assumed to be artifact until proven otherwise. Identifying severe thrombocytopenia as the cause of the "artificial" or "nonheparin" source of ACT elevation, and then administering platelets without first (or simultaneously) increasing the heparin (despite the elevation of the ACT), risks an acutely clotted oxygenator or even the entire circuit, as the measured ACT returns into the normal range.
The heterogeneity of this study population reflects the variety of patients we all treat and care for on ECMO, and yet to lump them together in our assessment of ACT's reflection of heparin activity is misguided. Although I am sure no ECMO physician would expect the same ACT accuracy in a routine infant with respiratory failure from meconium aspiration when compared to a 3-year-old patient with severe methicillinresistant Staphylococcus aureus sepsis, still we tend to treat them identically when we approach their anticoagulation management, as well as other ECMO management. For example, despite the wide variety of patients in the study, they used the institutional transfusion criteria of a hematocrit of 35%. However, I would argue that 35% is likely an insufficient oxygen carrying capacity for a single ventricle patient with expected arterial oxygen saturations of 75% and perhaps unnecessarily high for a 12-year-old with myocarditis and normal lungs. Thirty-five percent may also be inadequate in a 10-year-old patient on venovenous ECMO for respiratory failure early in the course with a resultant saturation of 75%, and yet 30% or less would be more than sufficient after the lungs have improved and they are weaning off ECMO. Rather than setting an absolute "ideal" hemoglobin or hematocrit for all patients on ECMO, we should evaluate each patient's need based on oxygen delivery and lactate production. Similarly, treating all ECMO patients the same in our techniques of monitoring and management of circuit anticoagulation and patient coagulation is just as short sighted and, in doing so, we may find ourselves overtreating numbers and levels that we do not completely understand and potentially lead to more circuit and patient complications, rather than the reduction that we seek.
I do believe that additional tests to assess heparin effect such as anti-Xa can be extremely useful as an adjunct to more practical bedside testing, particularly when it goes awry or is confusing. However, that does not mean we can flush the use of bedside ACT or simply ignore the results. Clearly, our patients' conditions and coagulation states change more often than we can practically obtain more specific testing. As we continue to investigate a variety of measures of anticoagulation, including anti-Xa, thromboelastogram Factor VIII activity, and antithrombin III, we must first better understand the implications of the tests and their application to individual patients and individual states of coagulation as effected by sepsis, organ failure, inflammatory mediators, and other factors related to the underlying condition that led to their requiring ECMO support. I applaud the presentation of the data by the authors, but more importantly their cautionary approach to their conclusions. Their work along with similar work by groups in Michigan, Houston, and the United Kingdom (as referenced in the article) will provide essential information on this process. In addition, the Extracorporeal Life Support Organization is kicking off its next task force directed specifically at these issues. We must all continue to work toward a more complete understanding of the complex interactions among the blood, artificial surfaces, and the inflammatory response to disease to better manipulate and modify these processes to achieve our common goal of having a patient that will form appropriate clot, supported by a circuit that won't!
